By / December 18, 2019

Clever Leaves receives quota for high-THC medical cannabis

Clever Leaves, a company with a global presence that consolidates itself as a world leader, received one of the most relevant quotas for the cultivation and manufacture of psychoactive cannabis for the good development of the industry in the country.

You can find more information about the marijuana industry and other important news in the cannabis sector in the app. This app collects the latest hemp news among cannabis sectors that investors operate in.

Clever Leaves receives largest quota of its kind in the country

Colombia has one of the most robust and comprehensive regulations against the development of the medical cannabis industry. This regulation, coupled with strategic geographical advantages and a favorable political environment, makes Colombia a major global power.

In the framework of the development of the industry on Nov. 29, 2019, the National Government granted Clever Leaves quotas for the cultivation of medical cannabis with high-THC.

This quota, with commercial purposes, will be destined to the elaboration of medical-grade products for patients worldwide, reinforcing the positioning of Clever Leaves as pioneers in the industry.

This quota designation is believed to be the largest of its kind issued to a Colombian licensed producer.

Clever Leaves aims to be pioneers in the industry

“Clever Leaves has positioned itself as a pioneer producer in the medical cannabis industry in Colombia. With this authorization, the company strengthens its image as an export leader in Latin America capable of legally reaching all markets around the world that allow its commercialization. Prior to the designation of this quota, Colombia stood out largely for its hemp, and now, this achievement marked the formal entry of Clever Leaves and Colombia into the growing international medical cannabis industry,” said Kyle Detwiler, CEO of Clever Leaves.

In order to obtain the quota, Clever Leaves had to demonstrate its commitment and responsible process to governmental institutions during the stages of investigation and stabilization of the cannabis varieties that it cultivates, as well as the scientific trials to obtain extracts and products with stability and security for the patients.

Doctor sitting at desk representing Clever Leaves CEO
Clever Leaves will soon begin the production of medical cannabis in Colombia. (Source)

The future of the company

It should be remembered that Clever Leaves is the only medical cannabis company whose laboratory has Good Manufacturing Practice (GMP) certification from Invima, which affirms the pharmaceutical quality of its products.

“Our team in Colombia has worked diligently to comply with the rigorous regulatory process to obtain the quota mentioned by the National Government. We hope to increase our share in the coming years in order to become the largest exporters of cannabis with high THC content, which will leverage us to meet the demand of patients around the world with pharmaceutical grade products,” said Andrés Fajardo, President of Clever Leaves.


(Featured image by Thought Catalog via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in EJE21, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Comments are closed for this post.